Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07295324
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
PF-07295324 is an experimental small molecule drug developed by Pfizer as a topical "soft" Janus kinase (JAK) inhibitor. Its mechanism of action involves inhibiting Janus kinase enzymes, which play a key role in cytokine signaling pathways implicated in inflammatory diseases. The compound was designed for minimal systemic exposure and was investigated primarily for the treatment of atopic dermatitis (eczema). Clinical development reached Phase 1 trials with topical administration in healthy volunteers to assess safety and tolerability. As of the latest available information, it has not been approved for any indication.
02
Targets
JAK (Janus kinase family)
Beyond the preview
Go deeper on PF-07295324.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07295324.